{"id":"W2293077587","doi":"10.1016/s0140-6736(16)00559-6","title":"Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":638,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; American College of Radiology Imaging Network","keywords":"Sunitinib; Sorafenib; Medicine; Renal cell carcinoma; Placebo; Oncology; Internal medicine; Adjuvant; Clinical endpoint; Clinical trial; Pathology; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001849571,0.0025183,0.004558338,0.0004369086,0.0004500418,0.001105628,0.0009650182,0.002004779,0.007958602],"category_scores_gemma":[0.001477093,0.0008260565,0.002756242,0.000441518,0.001325861,0.001270768,0.0004155714,0.003390019,0.001433677],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008459775,"about_ca_system_score_gemma":0.001049958,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001405398,"about_ca_topic_score_gemma":0.003730433,"domain_scores_codex":[0.9994167,0.0002765524,0.00003555003,0.0001221648,0.00004066078,0.000108443],"domain_scores_gemma":[0.9993935,0.0001773508,0.0001317302,0.00004797565,0.00003723027,0.0002122113],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9846939,0.001616978,0.0001911281,0.001183605,0.001101416,0.00002994115,0.00003671778,0.0002862703,0.001296147,0.00009725778,0.0009192944,0.008547416],"study_design_scores_gemma":[0.9813214,0.01698839,0.0005349949,0.00002843434,0.0003411724,0.00002105182,0.00001082921,0.0001889264,0.0001206195,0.0001082217,0.0003261654,0.000009896579],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.969864,0.01611358,0.001550397,0.001334399,0.001655061,0.004203612,0.001749119,0.0004210964,0.003108795],"genre_scores_gemma":[0.9801413,0.006162989,0.001610641,0.001436179,0.0005985785,0.002991366,0.00128674,0.00004423103,0.005728076],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007958602,"threshold_uncertainty_score":0.02662414,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07669057324285966,"score_gpt":0.3304014740191872,"score_spread":0.2537109007763276,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}